ATE310247T1 - Verfahren zur bestimmung von normalem aglycan, bestimmungssatz und verfahren zur beurteilung von informationen bezüglich der gelenke - Google Patents

Verfahren zur bestimmung von normalem aglycan, bestimmungssatz und verfahren zur beurteilung von informationen bezüglich der gelenke

Info

Publication number
ATE310247T1
ATE310247T1 AT95909102T AT95909102T ATE310247T1 AT E310247 T1 ATE310247 T1 AT E310247T1 AT 95909102 T AT95909102 T AT 95909102T AT 95909102 T AT95909102 T AT 95909102T AT E310247 T1 ATE310247 T1 AT E310247T1
Authority
AT
Austria
Prior art keywords
joint
normal
information
aggrecan
normal aggrecan
Prior art date
Application number
AT95909102T
Other languages
English (en)
Inventor
Satosi Miyauti
Katuyuki Horie
Original Assignee
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Kogyo Co Ltd filed Critical Seikagaku Kogyo Co Ltd
Application granted granted Critical
Publication of ATE310247T1 publication Critical patent/ATE310247T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Inspection Of Paper Currency And Valuable Securities (AREA)
AT95909102T 1994-02-19 1995-02-17 Verfahren zur bestimmung von normalem aglycan, bestimmungssatz und verfahren zur beurteilung von informationen bezüglich der gelenke ATE310247T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5973994 1994-02-19
PCT/JP1995/000220 WO1995022765A1 (fr) 1994-02-19 1995-02-17 Procede de dosage de l'aglycane normal, trousse de dosage et procede d'evaluation des informations relatives aux articulations

Publications (1)

Publication Number Publication Date
ATE310247T1 true ATE310247T1 (de) 2005-12-15

Family

ID=13121899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909102T ATE310247T1 (de) 1994-02-19 1995-02-17 Verfahren zur bestimmung von normalem aglycan, bestimmungssatz und verfahren zur beurteilung von informationen bezüglich der gelenke

Country Status (7)

Country Link
US (1) US5948692A (de)
EP (1) EP0745850B1 (de)
JP (1) JP3694894B2 (de)
AT (1) ATE310247T1 (de)
AU (1) AU705059B2 (de)
DE (1) DE69534619T2 (de)
WO (1) WO1995022765A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE259505T1 (de) * 1996-08-15 2004-02-15 Novartis Pharma Gmbh Test zur quantifizierung von arthritiszustanden
US5869273A (en) * 1996-09-13 1999-02-09 Glyko, Inc. Chondroitin sulfate as a marker of bone resorption
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
US6705930B2 (en) * 2000-01-28 2004-03-16 Lam Research Corporation System and method for polishing and planarizing semiconductor wafers using reduced surface area polishing pads and variable partial pad-wafer overlapping techniques
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
JP4049312B2 (ja) * 2000-08-29 2008-02-20 イメージング セラピューティクス，インコーポレーテッド Ｘ線画像の定量解析法および装置
US7660453B2 (en) * 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
EP1389947B1 (de) * 2001-05-25 2009-08-26 Imaging Therapeutics, Inc. Verfahren zur diagnose, behandlung und prävention von knochenverlust
AU2002330085A1 (en) * 2001-09-24 2003-05-26 Mount Sinai School Of Medicine Methods and compositions for therapeutic treatment of cathepsin k complex-mediated disorders
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
WO2004086972A2 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
EP1663002A4 (de) * 2003-09-19 2007-11-28 Imaging Therapeutics Inc Verfahren für die knochenstrukturprognose und simulierte knochenremodellierung
US8290564B2 (en) * 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
WO2007035397A1 (en) * 2005-09-15 2007-03-29 The Regents Of The University Of Michigan Method and system for measuring cartilage condition biomarkers
JP2009512844A (ja) * 2005-10-20 2009-03-26 ノルディック・バイオサイエンス・ダイアグノスティクス・アクティーゼルスカブ アグリカンおよびそのフラグメントの検出または定量
CA2651185C (en) * 2006-05-09 2022-08-30 The University Of British Columbia Dissolved protein arthritis markers
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage
EP3418397B1 (de) 2012-01-24 2020-10-07 CD Diagnostics, Inc. System zum nachweis einer infektion in der synovialflüssigkeit
JP2018151206A (ja) * 2017-03-10 2018-09-27 一丸ファルコス株式会社 プロテオグリカン分析方法
EP3623816A1 (de) * 2018-09-12 2020-03-18 GLX Analytix ApS Glx-abgeleitete moleküldetektion
JP2020165937A (ja) * 2019-03-29 2020-10-08 国立大学法人弘前大学 プロテオグリカンの測定方法、評価方法および測定用キット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH642458A5 (en) * 1980-04-25 1984-04-13 Hoffmann La Roche Immunological method
CA1160566A (en) * 1980-04-25 1984-01-17 Harald Gallati Immunological determination method
SE8304836D0 (sv) * 1983-09-09 1983-09-09 Pharmacia Ab Sett att bestemma forendringar i ledbrosk
US5185245A (en) * 1989-02-24 1993-02-09 Thomas Jefferson University Immumoassays and kit for detection of proteoglycans
US5032281A (en) * 1989-08-09 1991-07-16 Daicel Chemical Industries, Ltd. Separating membrane and separation method

Also Published As

Publication number Publication date
EP0745850A1 (de) 1996-12-04
DE69534619D1 (de) 2005-12-22
EP0745850A4 (de) 2003-05-28
DE69534619T2 (de) 2006-07-13
JP3694894B2 (ja) 2005-09-14
AU705059B2 (en) 1999-05-13
AU1717795A (en) 1995-09-04
WO1995022765A1 (fr) 1995-08-24
US5948692A (en) 1999-09-07
EP0745850B1 (de) 2005-11-16

Similar Documents

Publication Publication Date Title
ATE310247T1 (de) Verfahren zur bestimmung von normalem aglycan, bestimmungssatz und verfahren zur beurteilung von informationen bezüglich der gelenke
EP0805215A3 (de) Diagnostische Methoden und Proben
DE502005005132D1 (de) Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen
Fex et al. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet.
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
CY1111229T1 (el) Μεθοδος προσδιορισμου ρευματοειδους αρθριτιδας με μετρηση αντι-ccp και ιντερλευκλινης 6
DK1513878T3 (da) Sammensætninger og fremgangsmåder til analyse af Apo B48 og Apo B100
ES2101802T3 (es) Ensayo para determinar los niveles de igf-i, igf-ii y gh libres en liquidos corporales.
DE69941627D1 (de) Für krebs
ATE401342T1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
US5185245A (en) Immumoassays and kit for detection of proteoglycans
Laurell Electrophoresis, specific protein assays, or both in measurement of plasma proteins?
DE69736336D1 (de) Verfahren zur messung von blutersatzstoffen
KR960705211A (ko) 체액내 bpi의 정량 방법(method for quantifying bpi in body fluids)
Pugia et al. Clinical utility of a rapid test for uristatin
Gounden et al. Urine specific gravity measurements: comparison of a new reagent strip method with existing methodologies, as applied to the water concentration/dilution tests
DE69414871D1 (de) Verfahren zur bestimmung der quantität extrazellulärer bpi in körperflüssigkeiten
ATE287084T1 (de) Immunoassay verfahren und testsatz
Bowles et al. Changes in serum bone-specific alkaline phosphatase following tibial fracture
FI990380A (fi) Diagnostinen ja seulontamenetelmä
Farrell et al. Low-Cost Optical Transmittance Measurements for the Detection and Quantification of Agglutination in Dual-phase Lab-in-Tubing Microfluidics
DE59808639D1 (de) Verfahren zur bestimmung von schilddrüsen-autoantikörpern
Erickson et al. Performance Evaluation of an ELISA for the Quantitative Measurement of α1-Antitrypsin in Stool
ATE186600T1 (de) Phosphattest
CA2183589A1 (en) Method of assaying normal aggrecan, assaying kit, and method of judging joint-related information

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties